ONGLYZA™ (saxagliptin) U.S. Label Update Provides Further Evidence Regarding ... - Business Wire (press release) PDF Print
Business Wire (press release)
The renal study investigated the safety and efficacy of ONGLYZA in patients with moderate to severe renal impairment or end-stage renal disease (ESRD). The 12-week data showed that ONGLYZA 2.5 mg once daily significantly improved glycoslated hemoglobin

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.